Few subjects in aesthetic plastic surgery generate as much emotion—or as much online certainty—as breast implant illness, commonly abbreviated BII.

Women who describe BII may be genuinely suffering. Some report dramatic improvement after their breast implants are removed. Others do not. Meanwhile, social media can transform a complicated scientific question into something deceptively simple: I had implants. I became sick. The implants made me sick.

Perhaps they did.

But medicine requires us to distinguish what is possible, what is associated, and what has actually been demonstrated.

That distinction is not medical gaslighting. It is the purpose of science.

My goal here is neither to defend breast implants nor to dismiss women who believe their implants have made them ill. I implant breast implants. I remove them. I revise them. I have no philosophical allegiance to a silicone bag.

Instead, I want to take some of the temperature out of an understandably emotional discussion and examine what we actually know—and, just as importantly, what we don’t.

What Is Breast Implant Illness?

Breast implant illness is a term used by patients and physicians to describe a broad constellation of systemic symptoms reported by some women with breast implants.

Commonly reported symptoms include:

• Chronic fatigue
• “Brain fog,” memory or concentration problems
• Joint and muscle pain
• Headaches
• Hair loss
• Weight changes
• Anxiety and depression
• Sleep disturbances
• Various other nonspecific systemic complaints

The FDA acknowledges these reports in women with both silicone- and saline-filled implants. But as of 2026, the FDA also states something critically important: BII is not recognized as a formal medical diagnosis, and there are no specific tests or recognized diagnostic criteria that define it.

In other words, there is presently no blood test, imaging study, antibody, pathological finding or other validated biomarker that allows a physician to say:

“This patient has breast implant illness.”

That doesn’t mean the symptoms aren’t real.

It means we don’t yet know what those symptoms represent—or, in an individual patient, what caused them.

We’ve Been Down a Similar Road Before

I was practicing plastic surgery during the great silicone breast implant controversy of the 1990s.

At the time, silicone implants were accused of causing rheumatoid arthritis, lupus, scleroderma, Sjögren’s syndrome and other connective-tissue and autoimmune diseases. Media attention and litigation exploded, and silicone implants were restricted in the United States outside controlled circumstances.

The controversy also triggered an extraordinary amount of research.

In 1995, investigators analyzing 87,501 women in the Nurses’ Health Study found no association between breast implants and defined connective-tissue diseases. Importantly, their follow-up data largely preceded the widespread media attention surrounding the controversy.¹

In 2000, a New England Journal of Medicine meta-analysis combined 20 epidemiologic studies and again found no evidence that breast implants produced a meaningful increase in the major connective-tissue diseases being investigated.²

The FDA today similarly states that it has not detected an association between silicone gel-filled breast implants and connective-tissue disease.⁷

That does not prove that implants cannot cause systemic symptoms through some mechanism that we have yet to understand.

It does demonstrate why anecdote and biological causation cannot be treated as synonyms.

The 1990s Implant Litigation Is Worth Remembering

The history is particularly interesting because the scientific debate did not occur in a vacuum.

A 2010 article in the AMA Journal of Ethics reviewed the extraordinary breast-implant litigation of the 1990s and described the collision among public fear, litigation, physicians, manufacturers and emerging scientific evidence. It noted that early jury verdicts occurred before the epidemiological evidence matured and that later independent scientific reviews increasingly failed to support the sweeping autoimmune claims being made at the time.⁸

Some historical implant research did have industry involvement, and potential conflicts of interest deserve scrutiny. But the evidence cannot accurately be dismissed as simply “research paid for by breast implant companies.” Major work was also supported by government and independent sources.

So yes: follow the money. But follow it in both directions.

Industry conflicts matter. So do litigation conflicts, advocacy bias and professional incentives.

Science ultimately has to stand on whether findings can be reproduced by different investigators, in different populations, using different methods.

The Pesky Little Problem: Silicone Is Everywhere

Here is another part of the discussion that rarely receives enough attention.

Silicone is ubiquitous.

Silicone isn’t one chemical. It is a family of silicon-oxygen-containing compounds with dramatically different molecular sizes and properties.

Small cyclic volatile methylsiloxanes such as D4, D5 and D6 have been demonstrated in tissues surrounding silicone breast implants. Gel bleed and migration of certain low-molecular-weight siloxanes through an intact implant shell are real phenomena.⁵

But those same families of siloxanes aren’t unique to breast implants.

They are widely encountered in our everyday environment and are used in personal-care products, including cosmetics, antiperspirants and particularly hair-care products. Studies of indoor environments identify personal-care products as an important source of human exposure to volatile methylsiloxanes.

A particularly fascinating 2023 study actually measured emissions during ordinary hair-care routines. D5 was the predominant cyclic siloxane emitted. Under one modeled poorly ventilated bathroom scenario, the estimated cumulative D5 inhalation during a 20-minute hair-care routine reached approximately 17 milligrams. Turning on the exhaust fan substantially reduced that exposure.⁶

That certainly does not prove that hairspray is safer or more dangerous than a breast implant. These are completely different exposure circumstances and should not be treated as a head-to-head toxicological comparison.

But it raises an important scientific question.

If the proposed culprit is simply “silicone,” then we have to ask:

Which silicone? From where? At what dose? By what route? Over what period of time? And through what biological mechanism?

Simply pointing at the two most obvious pieces of silicone in the room and declaring those twins guilty doesn’t answer those questions.

Association is not causation.

“But I Felt Better After My Implants Were Removed”

This is perhaps the most compelling argument made by women who believe they have experienced BII.

And it deserves to be taken seriously.

A 2025 systematic review and meta-analysis involving 33 studies and more than 6,000 women reported that approximately 82% of patients reported some symptom improvement following explantation. Another systematic review found similarly high rates of patient-reported improvement.³

That is interesting.

It deserves further study.

But it still does not, by itself, establish causation.

A 2026 systematic review and meta-analysis reached a more cautious conclusion: among patients categorized as having BII/systemic symptoms, most did not achieve complete resolution, average improvement was more moderate, and the authors emphasized considerable heterogeneity among the underlying studies.⁴

This is precisely why study design matters.

Imagine spending months or years convinced that a foreign object inside your body is poisoning you. You research it extensively. Perhaps you join online communities populated by people experiencing similar symptoms. Eventually, you undergo surgery and the object you have come to fear is finally removed.

The surgery goes well.

Someone then asks:

“Do you feel better?”

That is hardly a double-blinded experiment.

Expectancy effects, placebo effects, reversal of a nocebo effect and confirmation bias are legitimate potential confounders. That doesn’t mean the patient’s improvement isn’t genuine. It means improvement alone cannot tell us why she improved.

I sometimes describe this as the surgical equivalent of confirmation bias.

The FDA takes an appropriately cautious position: some women report improvement or resolution following explantation, but the cause of these systemic symptoms and the degree to which they are related to the implants remain unclear.⁷

There is an important lesson here:

“We don’t know yet” has to cut both ways.

It cannot be used simultaneously to argue that science doesn’t understand BII and that science has therefore established that implants caused it.

What I Tell My Patients Who Want Their Implants Removed

When a woman comes to me and says:

“Doctor, I believe I have breast implant illness and I want my implants removed.”

My answer is quite straightforward.

You’ve come to the right place. I’m a plastic surgeon. Removing breast implants is part of what I do.

If a woman no longer wants implants in her body, that alone is a legitimate reason to remove them. She doesn’t need to convince me that she has BII.

But before surgery, I owe her something considerably more valuable than agreement:

informed consent.

I can promise to remove her implants.

I cannot honestly promise that removing them will cure her fatigue, brain fog, joint pain, headaches, anxiety or whatever systemic symptoms she has attributed to them.

If she understands that uncertainty and still wants her implants removed?

Absolutely. Off we go.

Because my responsibility as a surgeon isn’t to tell a patient what she wants to hear—or what the implant industry, plaintiffs’ attorneys, Facebook groups or anyone else wants her to hear.

It is to tell her what we know, what the evidence suggests, and what we still don’t know.

That isn’t dismissing women’s symptoms.

It is taking them seriously enough not to pretend that medicine has answers it does not yet possess.

The Bottom Line on Breast Implant Illness

Breast implant illness remains an evolving and controversial area of medicine.

Women reporting these symptoms deserve to be heard. Their symptoms should be investigated rather than automatically attributed to implants—or automatically dismissed. And women who decide they no longer want breast implants should have access to thoughtful explantation counseling.

At the same time, medicine should resist replacing one form of dogma with another.

The emerging literature suggesting an association between implants, systemic symptoms and improvement after explantation deserves serious investigation. In fact, a 2025 meta-analysis found BII-type symptoms were reported more frequently among women with implants for several symptom categories. That is a signal worth studying, not ignoring.³

But a signal is the beginning of a scientific investigation, not the end of one.

Perhaps we will ultimately identify an inflammatory, immunological, microbial, genetic or other mechanism that explains systemic symptoms in a susceptible subset of women. Perhaps what we currently call BII will ultimately prove to encompass several different conditions.

I don’t know. Neither does anyone else yet.

And for the moment, that may be the most scientifically honest answer of all.

Frequently Asked Questions

Is breast implant illness a recognized medical diagnosis?

Currently, the FDA states that BII is not recognized as a formal medical diagnosis and that there are no specific diagnostic tests or recognized criteria defining it.⁷

What are the most common BII symptoms?

Reported symptoms include fatigue, brain fog, joint and muscle pain, hair loss, weight changes, anxiety and depression.

Do symptoms improve after breast implant removal?

Many patients report improvement following explantation, and systematic reviews have documented substantial patient-reported improvement. However, studies are heterogeneous, and improvement following removal does not by itself establish the biological mechanism responsible.^3,4

Is there proof that breast implants cause autoimmune disease?

The FDA currently states that it has not detected an association between silicone gel-filled breast implants and connective-tissue disease, although research into systemic symptoms associated with implants continues.⁷

Does breast implant removal require a total capsulectomy for BII?

The evidence does not currently establish that every patient seeking explantation for systemic symptoms requires total capsulectomy. The appropriate surgical approach should be individualized according to implant and capsule findings, medical indications and patient circumstances.

Selected Scientific References

1. Sánchez-Guerrero J, et al. Silicone Breast Implants and the Risk of Connective-Tissue Diseases and Symptoms. New England Journal of Medicine. 1995;332:1666–1670.
2. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the Relation Between Silicone Breast Implants and the Risk of Connective-Tissue Diseases. New England Journal of Medicine. 2000;342:781–790.
3. Ferreira S, Barros AS, Marques M. Breast Implant Illness: Symptoms, Outcomes with Explantation and Potential Etiologies—A Systematic Review and Meta-analysis. Aesthetic Plastic Surgery. 2025.
4. Cuenca-Pardo J, et al. Breast Implant Explantation and Capsulectomy in Symptomatic Patients. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2026.
5. Flassbeck D, et al. Determination of Siloxanes, Silicon, and Platinum in Tissues of Women With Silicone Gel-Filled Implants. Analytical and Bioanalytical Chemistry. 2003.
6. Jung N, et al. Siloxane Emissions and Exposures During the Use of Hair Care Products in Buildings. Environmental Science & Technology. 2023.
7. FDA. Medical Device Reports for Systemic Symptoms in Women with Breast Implants.
8. Schleiter KE. Silicone Breast Implant Litigation. AMA Journal of Ethics. 2010.

Randal D. Haworth, MD, FACS
Board-Certified Plastic Surgeon | Beverly Hills